Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection

Mark S. Sulkowski, Hugo E. Vargas, Adrian M. Di Bisceglie, Alexander Kuo, K. Rajender Reddy, Joseph K. Lim, Giuseppe Morelli, Jama M. Darling, Jordan J. Feld, Robert S. Brown, Lynn M. Frazier, Thomas G. Stewart, Michael W. Fried, David R. Nelson, Ira M. Jacobson, N. Afdhal, I. Alam, Z. Ben-Ari, J. Bredfeldt, R. S. BrownR. T. Chung, J. Darling, W. Harlan, A. M. Di Bisceglie, R. C. Dickson, H. A. Elbeshbeshy, G. Everson, J. Feld, J. M. Fenkel, M. W. Fried, J. Galati, S. C. Gordon, M. Hassan, T. N. Hawkins, F. Hinestrosa, I. M. Jacobson, C. A. Kerr, A. Kuo, P. Y. Kwo, J. Levitsky, J. Lim, A. S. Lok, M. Mailliard, M. P. Manns, G. Morelli, A. J. Muir, D. Nelson, J. G. O'Leary, B. L. Pearlman, P. Pockros, HCV-TARGET Study Group

Research output: Contribution to journal › Article › peer-review

153 Scopus citations

Fingerprint

Dive into the research topics of 'Effectiveness of Simeprevir Plus Sofosbuvir, with or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection'. Together they form a unique fingerprint.

Medicine & Life Sciences